The number of conventional type I dendritic cells (cDC1) in the tdLN decreased during tumour growth, but treatment with Fms‐like tyrosine kinase‐3 ligand (Flt3L) plus anti‐CD40 led to cDC1 maturation, followed by the recovery of Tpex cell frequencies and a reduction in the tumour burden.13 The gene discussed is FLT3LG; the disease is neoplasm.